The U.S. Food and Drug Administration has approved Johnson & Johnson’s RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first subcutaneous version of its bispecific EGFR-MET antibody therapy, for patients with EGFR-mutated non-small cell lung cancer (NSCLC). The approval spans all current RYBREVANT indications and is based on the Phase 3 PALOMA-3 study, which demonstrated comparable pharmacokinetics to the intravenous formulation and lower rates of administration-related reactions. RYBREVANT FASPRO is co-formulated with Halozyme’s recombinant hyaluronidase technology and is administered in combination with LAZCLUZE (lazertinib), offering an entirely subcutaneous, chemotherapy-free option for frontline EGFR-mutated NSCLC.

Why this approval shifts the conversation around frontline EGFR+ NSCLC therapy

The U.S. Food and Drug Administration’s approval of a subcutaneous formulation of amivantamab marks a significant inflection point in how epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is treated—not just in terms of therapeutic efficacy, but in the operational and human experience of care. More than a simple route-of-administration update, the approval of RYBREVANT FASPRO redefines how treatment logistics, patient throughput, and regimen tolerability are optimized in the oncology setting.

Previously, the intravenous (IV) delivery of RYBREVANT (amivantamab-vmjw) required infusion sessions that could stretch over several hours, posing scheduling challenges for both hospitals and patients, while contributing to high rates of administration-related reactions (ARRs). The subcutaneous (SC) RYBREVANT FASPRO formulation, co-developed using Halozyme’s ENHANZE delivery platform, now condenses this into a five-minute injection without compromising drug exposure or efficacy. PALOMA-3 data confirmed not only pharmacokinetic non-inferiority to the IV formulation but also a dramatic drop in ARRs—from 66% with IV to just 13% with SC administration. That fivefold reduction has immediate implications for both safety management and health system resource allocation.

This change is particularly relevant as cancer centers and infusion clinics navigate staffing shortages, overbooked infusion chairs, and a growing emphasis on value-based care. Oncology administrators and care coordinators are increasingly incentivized to identify regimens that combine therapeutic efficacy with operational simplicity. From this perspective, RYBREVANT FASPRO is a strong contender for standard-of-care inclusion in first-line EGFR+ NSCLC regimens—not just because it works, but because it works in a way that aligns with evolving care delivery models.

Industry analysts also point out that this new delivery model allows Johnson & Johnson to compete more directly with third-generation oral EGFR tyrosine kinase inhibitors (TKIs) like osimertinib, which have traditionally been favored for their ease of use and outpatient-friendly profile. RYBREVANT FASPRO, when combined with LAZCLUZE (lazertinib), offers a dual-targeted, chemotherapy-free regimen that is not only clinically differentiated, but also logistically simplified—removing the need for infusion center visits, venous access devices, and post-infusion monitoring.

From a patient-centered care standpoint, clinicians suggest the benefits of a five-minute SC injection extend beyond mere convenience. For elderly patients, those with limited mobility, or those living far from tertiary cancer centers, shorter administration times may directly translate into better adherence and fewer treatment delays. These real-world factors, often underrepresented in clinical trial endpoints, are gaining greater recognition as determinants of long-term survival and quality of life in EGFR-mutated lung cancer.

In addition, the subcutaneous route opens the door to future home-based oncology care models. As healthcare systems globally re-evaluate which treatments truly require in-clinic administration, subcutaneously administered monoclonal antibodies could enable decentralization—bringing cancer therapy into the home setting under nurse supervision or even through self-injection protocols in select cases. For RYBREVANT FASPRO, this trajectory may be accelerated by the already established safety data and favorable tolerability profile observed in PALOMA-3, especially when compared to traditional IV monoclonal antibodies that often trigger systemic infusion reactions.

Taken together, the shift from IV to SC delivery for amivantamab is more than a formulation swap. It is a strategic move that aligns with multiple macro-level oncology trends: a push toward chemo-free regimens, a pivot to decentralized care, and a rising expectation that biologic therapies must deliver not just efficacy but also minimal disruption to patients’ daily lives.

From market access, health economics, and patient experience standpoints, RYBREVANT FASPRO positions Johnson & Johnson as a frontrunner in the race to define the next generation of targeted lung cancer care—one that is not only more precise, but also more humane, scalable, and system-friendly.

What PALOMA-3 data reveals about durability, tolerability, and comparative survival

The PALOMA-3 trial did more than show non-inferior pharmacokinetics. It revealed outcome differentials favoring the subcutaneous arm across multiple secondary endpoints. Median overall survival (OS) was higher in the subcutaneous RYBREVANT FASPRO plus LAZCLUZE arm (hazard ratio 0.62; 95% CI: 0.42–0.92; P=0.02), with 65% of patients alive at 12 months compared to 51% in the IV arm.

This adds further weight to the original MARIPOSA study findings, where the intravenous RYBREVANT and LAZCLUZE combination showed a statistically significant OS benefit versus osimertinib. The projected median OS for the IV combination exceeds four years—over one year longer than the 36.7-month benchmark with osimertinib. Now, with a subcutaneous formulation showing enhanced tolerability, lower venous thromboembolism incidence (11% SC vs 18% IV), and improved patient-reported outcomes, the totality of data suggests a frontline option with strong potential to displace chemotherapy and oral TKIs in select EGFR+ populations.

What this enables in managing EGFR resistance and disease progression

One of the more strategic implications of the RYBREVANT FASPRO approval lies in its potential to delay or suppress resistance mechanisms that undermine long-term EGFR-directed therapy. The MARIPOSA study demonstrated a significant reduction in acquired resistance, including MET amplification and secondary EGFR mutations such as C797S. Only 3% of patients on the RYBREVANT plus LAZCLUZE combination developed MET amplifications compared to 13% on osimertinib, while C797S mutations dropped from 8% to 1%.

These data suggest that dual targeting of EGFR and MET via amivantamab may suppress escape pathways that typically emerge within 6–12 months of monotherapy. From a biological standpoint, industry analysts believe the RYBREVANT-based combination is altering the natural history of the disease rather than just prolonging response. For regulatory watchers and reimbursement committees, the ability to reduce resistance-driven treatment switches may justify the premium associated with biologic-based combinations.

What regulatory clarity means for near-term commercial momentum

Unlike many subcutaneous reformulations that require bridging studies and fresh approvals, RYBREVANT FASPRO was cleared across all previously approved IV indications, including frontline use with LAZCLUZE and second-line use in exon 20 insertion–mutated NSCLC. The seamless regulatory path owes much to PALOMA-3’s dual pharmacokinetic endpoints and strong secondary efficacy measures.

From a commercial standpoint, this expands physician prescribing options without requiring retraining or restrictive coverage negotiations. With the product now eligible for use in both the first- and second-line settings, alongside established National Comprehensive Cancer Network (NCCN) Category 1 recommendations, the reimbursement framework is relatively well defined. Johnson & Johnson has also expanded its RYBREVANT withMe patient support program to cover the FASPRO formulation, offering cost assistance, prior authorization navigation, and personalized care guidance.

What remains uncertain as subcutaneous biologics expand in oncology

Despite its convenience and improved tolerability, RYBREVANT FASPRO still faces two interrelated challenges: first, ensuring adequate real-world safety data accumulates to support broad adoption beyond academic centers; and second, defining its positioning relative to emerging fourth-generation TKIs and novel bispecifics entering late-stage trials.

Adoption may also be influenced by administration logistics in certain clinics. Although five-minute manual injection is faster than IV infusions, subcutaneous monoclonal antibody delivery can still require observation time for potential injection-site reactions or delayed hypersensitivity responses. Additionally, manufacturing scalability of combination products involving recombinant hyaluronidase (rHuPH20) remains a consideration for broader rollouts.

While the product’s profile is largely consistent with IV delivery, adverse reactions such as rash, nail toxicity, peripheral neuropathy, and pruritus remain common and require proactive dermatologic management. Clinicians will also need to educate patients on signs of delayed thromboembolic events, particularly given ongoing anticoagulation recommendations in the first four months of treatment.

  amivantamab, bispecific antibodies, EGFR-mutated NSCLC, ENHANZE technology, FDA, Johnson & Johnson, LAZCLUZE, lazertinib, lung cancer, MARIPOSA, oncology approvals, PALOMA-3, RYBREVANT FASPRO, subcutaneous biologics